Xyphos Biosciences Inc.

Genentech, Inc.

Kyle Landgraf

Daniel P Steiger

David W Martin, Jr

Steven R Williams

Dana Gebhart

Tarah Baron

Robert A Lazarus

Daniel Steiger

Kaman C Kim

David W Martin

This present disclosure relates generally to the production of polypeptides comprised of modified α1-α2 domains of NKG2D ligands which bind specifically to a non-natural ectodomain of a non-natural NKG2D receptor and wherein heterologous molecules are attached to the modified α1-α2 domains of NKG2D ligands. The present disclosure further relates to modified α1-α2 domains of NKG2D ligands attached to heterologous molecules including polypeptides, and in some embodiments, antibodies or fragments of antibodies. The present disclosure also relates to modified forms of the NKG2D receptor engineered to provide a combination of enhanced and diminished binding to non-natural and natural versions of NKG2D ligands, respectively.

Modified A1-A2 domains of non-natural NKG2D ligands that bind non-natural NKG2D receptors

This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands.

Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands

This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands. This application further relates to modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.

Insertable variable fragments of antibodies and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands

Insertable variable fragments of antibodies and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors

Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.

Zymogen activators

Growing community of inventors

Alameda, CA, United States of America

Kyle Landgraf